0000000000650675

AUTHOR

Joaquin Mateo

showing 3 related works from this author

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology.

2021

Abstract The COVID-19 pandemic affected millions of people globally with lasting effects on society, patients, investigators and health institutions. Clinical trials, our best tool to improve cancer treatment for patients through testing the clinical value of a new treatment, have been affected by the pandemic. The pandemic footprint represents both a risk of compromising development of new therapies and an opportunity to elicit discussion over a portfolio of broader reforms, applicable irrespective of pandemics, in order to improve the design and implementation of clinical trials in oncology. The administrative load should be reduced, without affecting the quality of research and principle…

OncologyCancer ResearchTelemedicinemedicine.medical_specialtyOncologiamedia_common.quotation_subjectMedical Oncology:profesiones sanitarias::medicina::medicina interna::oncología médica [DISCIPLINAS Y OCUPACIONES]Quality of life (healthcare):características del estudio::estudio clínico::ensayo clínico [CARACTERÍSTICAS DE PUBLICACIONES]:Study Characteristics::Clinical Study::Clinical Trial [PUBLICATION CHARACTERISTICS]Internal medicinePandemic:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]medicinePandèmia de COVID-19 2020-HumansQuality (business):Health Occupations::Medicine::Internal Medicine::Medical Oncology [DISCIPLINES AND OCCUPATIONS]Pandemicsmedia_commonCOVID-19; Humans; Medical Oncology; Pandemics/prevention & control; SARS-CoV-2; TelemedicineSurrogate endpointSARS-CoV-2COVID-19:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]World populationTelemedicineClinical trialEditorialOncologyGood clinical practiceBusinessAssaigs clínicsESMO open
researchProduct

PI3K/AKT Activation and Response in Phase IB: AKT Inhibitor GDC-0068 with Docetaxel (D) Or MFOLFOX6 (F) in Refractory Solid Tumors

2013

R. Meng1, L. R. Molife2, L. de Mattos-Arruda3, A. Hollebecque4, S. J. Isakoff5, D. Roda6, Y. Yan1, A. Cervantes6, J. C. Soria4, J. Mateo2, G. Argiles3, J. C. Bendell7 Genentech, South San Francisco, CA, USA, Institute of Cancer Research/ Royal Marsden Hospital, Sutton, United Kingdom, Vall d’Hebron University Hospital, Barcelona, Spain, Institut Gustave Roussy, Villejuif, France, Massachusetts General Hospital, Boston, MA, USA, Institute of Health Research INCLIVA, University of Valenica, Valencia, Spain, Sarah Cannon Research Institute, Nashville, TN, USA

OncologySolid tumourmedicine.medical_specialtybusiness.industryHematologyAkt inhibitorUniversity hospitalInstitut Gustave RoussyOncologyDocetaxelInternal medicinemedicineGeneral hospitalbusinessProtein kinase BPI3K/AKT/mTOR pathwaymedicine.drugAnnals of Oncology
researchProduct

A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors.

2012

3021 Background: Activation of the Akt pathway is observed in multiple tumors and may contribute to chemoresistance. GDC-0068 is an ATP-competitive small molecule inhibitor of all three isoforms of Akt; in a phase Ia study, it was well tolerated with maximum tolerated dose (MTD) of 600 mg daily (21 days on/7days off) and pharmacodynamic down-regulation of Akt signaling in tumors at doses ≥100 mg. In vitro, GDC-0068 shows synergism with cytotoxic agents. This phase Ib study defines the dose limiting toxicities (DLT), MTD, safety and pharmacokinetics (PK) of GDC0068 in combination with D and F. Methods: Using a 3+3 designeligible patients (pt) with advanced/metastatic solid tumors were treat…

Gene isoformCancer Researchbusiness.industryAkt inhibitorSmall moleculeOncologyDocetaxelmedicineCancer researchIn patientMultiple tumorsbusinessPI3K/AKT/mTOR pathwaymedicine.drugJournal of Clinical Oncology
researchProduct